Capricor's DMD Cell Therapy Has HOPE, But Market Is Unsure
Capricor will start a Phase II trial in the first quarter of 2018 for its regenerative cell therapy CAP-1002 in Duchenne muscular dystrophy following positive results in an early-stage trial – the stem cell product was dropped by Capricor's big pharma partner Johnson & Johnson earlier this year.
You may also be interested in...
California biotech says it will move forward with knowledge and expertise gained through the failed partnership. Capricor hopes to re-partner CAP-1002 for cardiovascular indications, while continuing the candidate’s DMD development itself.
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.
The In Vivo team recently put a spotlight on innovation that might disrupt the pharma and medtech markets. Thinking about novel developments today that will impact the life sciences sector in the near future, we explored interesting new science, the convergence of R&D and technology, as well as what the future of surgery might look like.